Advances in genomic research and risk-directed therapy have led to improvements in the
long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic …

Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation
and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. IKZF1 …

Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

Glucocorticoids are a backbone of treatment for multiple myeloma in both the upfront and
relapsed/refractory setting. While glucocorticoids have single agent activity in multiple …

New therapies for Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like
ALL) patients are urgently needed. The genetic landscape of Ph-like ALL is characterized by …

While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) have
improved dramatically, survival rates for patients with relapsed/refractory disease remain …

Resistance to glucocorticoids (GC) is associated with an increased risk of relapse in B-cell
progenitor acute lymphoblastic leukemia (BCP-ALL). Performing transcriptomic and single …

Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a high
frequency of copy number alterations (CNAs) in IKZF1, EBF1, PAX5, CDKN2A/B, RB1 …

Advances in genomics have deepened our understanding of the biology of acute
lymphoblastic leukemia (ALL), defined novel molecular leukemia subtypes, discovered new …

B cells face multiple restrictions on glucose and energy metabolism. Their lineage-
determining transcription factors repress glucose uptake and pentose phosphate pathway …